Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Seasonal Allergic Rhinitis

In brief

To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis

Key facts

Study ID: NCT02125253
Run by: Amneal Pharmaceuticals, LLC
People needed: 811
Starts: 2014-01-01
Expected to finish: 2014-06-01
Last updated by the study team: 2015-11-02

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

If female and of child-bearing potential, have a negative urine pregnancy test and is prepared to abstain from sexual intercourse or use a reliable method of contraception during the study
Documented positive allergic skin test, performed within the previous 12 months, to one or more of the allergens in season at the time the study is being conducted.
A minimum of two consecutive years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the 12hours prior to the screening visit.
An average composite score of at least 6 on the rTNSS and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the last 3 days of the 7-day placebo lead-in period before the randomization visit and the morning of the first day.
of the randomization visit.

You may not qualify if…

Females who are pregnant, lactating or likely to become pregnant during the study.
Negative or lack of documented skin allergen test (performed within the previous 12 months) to at least one of the allergens in season at the time the study is being conducted.
Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis, unless the investigator assesses that the patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic Rhinitis (SAR) rather than chronic PAR.
Patients who suffer only from perennial allergic rhinitis or seasonal allergic rhinitis to a different allergen than that in season at the time the study is conducted.
Previous history of less than 2 years of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
Any patient who meets the minimum rTNSS requirements at the start of the placebo lead-in period but no longer meets the requirements prior to the randomized active treatment period of the study cannot continue in the active treatment period.
History of asthma over the previous two years that required chronic therapy. Occasional acute or mild exercise induced asthma will be allowable on the condition that the treatment of the attacks is restricted to beta-agonists only.
Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa or atrophic rhinitis.
Clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.
Sinus infection within the previous 30 days or history of reoccurring sinus infections.
Patient has started immunotherapy or changed their dose of immunotherapy within 30 days of the first placebo lead-in dose or is likely to have to start immunotherapy, or change their current dose during the study.
Treatment for oral Candidiasis within 30 days of starting the study or a current oral Candidiasis infection.
Upper respiratory tract infection within the previous 30 days.
Patients with a history of tuberculosis.
Patients with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of SAR within 14 days of enrollment.
The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
Patients with any untreated fungal, bacterial, systemic viral infections within the previous 30 days.
Use of any ophthalmic steroids within 14 days or nasal, inhaled or systemic steroids within 30 days of the study start.
Use of the reference product, Nasonex® within 3 months of the study start.
Use of intranasal or systemic second-generation anti-histamines within10 days of enrollment.
Use of intranasal cromolyn within 14 days of enrollment.
Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor antagonists or other nasal decongestants within 3 days of enrollment.
Use of any tricyclic anti-depressant within 30 days of enrollment
Patients with attention-deficit disorder being treated with methylphenidate containing products that have not been on a stable dosing regimen for at least the 30 previous days and who cannot remain on the same dosing regimen throughout the study.
Desensitization therapy to the seasonal allergen that is causing the patients allergic rhinitis within the previous 6 months.

Where it is running

Isis Clinical Research — Austin, Texas, United States
Austin Clinical Research — Austin, Texas, United States
Sirius Clinical Research — Austin, Texas, United States
Kerrville Research Associates — Kerrville, Texas, United States
Central Texas Health Research — New Braunfels, Texas, United States
Allergy & Asthma Research Center — San Antonio, Texas, United States
Biogenics Research Institute — San Antonio, Texas, United States
Diagnostics Research Group — San Antonio, Texas, United States
Sylvania Research — San Antonio, Texas, United States
Allergy & Asthma Care of Waco — Waco, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.